Roche's

The medicine, which was developed by Roche Holding AG and Novartis AG, which markets it in Europe, is under pressure from regulators, who are wary of the drug's high price amid attempts from doctors to use Roche's cheaper cancer treatment Avastin to treat vision loss.

U.K. Deals Blow to Roche, Novartis Goran Mijuk 2011

During this period, Lucentis could face fresh pressure in the U.S., where a study, sponsored by the U.S. National Eye Institute, compares the efficacy of Lucentis to that of Roche's Avastin in a 1,200 patient trial, results of which will be published this spring.

U.K. Deals Blow to Roche, Novartis Goran Mijuk 2011

The lower forecast is also due to the strong franc, Roche's reporting currency, which has risen markedly against the dollar last year.

EU Backs Avastin for Breast Cancer Goran Mijuk 2011

Positive pipeline news would be a boon to Roche's share price, which lost more than 20% during 2010 when a series of drug-development failures, negative regulatory verdicts and global austerity programs hurt its business.

EU Backs Avastin for Breast Cancer Goran Mijuk 2011

Avastin is Roche's best-selling drug, having netted around 6.4 billion Swiss francs $6.9 billion, in sales in 2010.

EU Backs Avastin for Breast Cancer Goran Mijuk 2011

Roche's Avastin failed to lengthen ovarian cancer patients' lives but stalled progression of the disease for a few months, newly reported studies said.

What's News— 2011

One painting found Mr. Roche's favor: a snowy scene with a small boy pulling a sled upon which was tied a Christmas tree.

Life Lessons From the Car Guy Bob Lutz 2011

That mechanism is similar to Lucentis and Roche's cancer drug Avastin, which is also used by some doctors to treat age-related macular degeneration.

Regeneron Drug Called Effective In FDA Review Jennifer Corbett Dooren 2011

Avastin, which accounted for about 16% of Roche's total sales in the first half, has hit hurdles lately that have threatened its wide success.

Drug Falls Short In Cancer Study Matt Jarzemsky 2011

"We are pleased that the European Commission is continuing to support Avastin in combination with chemotherapy," said Roche's chief medical officer Hal Barron .

EU Backs Avastin for Breast Cancer Goran Mijuk 2011